Skip to Main Content

Paper Details

Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.
Mol Oncol
68
2018
ER, ER protein, HER2, HER2 gene, HER2 protein, HER2+, HER2+ breast cancer, HER2+ breast tumors, HER2-positive (HER2+) breast cancer, Patients, breast cancer, breast tumors, estrogen, estrogen receptor, patient, patients, single tumor cells, tissue biopsies, tumor, tumors
Author NameAffiliation
Ole Christian Lingj??rdeInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Ole Christian Lingj??rdeUniversity of Oslo
Kornelia PolyakDana-Farber Cancer Institute
Kornelia PolyakDana-Farber Cancer Institute
Anne-Lise B??rresen-DaleInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Anne-Lise B??rresen-DaleUniversity of Oslo
Anne-Lise B??rresen-DaleInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Anne-Lise B??rresen-DaleUniversity of Oslo
Florian MarkowetzCambridge Institute, University of Cambridge
Florian MarkowetzCambridge Institute, University of Cambridge
  • 1 - 10

Datasets

Release 1.2